Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus

Arthritis Care and Research

Volumn 67, Issue 3, 2015, Pages 442-446

  Kiani, Adnan N ^a   Fang, Hong ^a   Akhter, Ehtisham ^a   Quiroga, Carmen ^b   Simpson, Nancy ^c   Alaupovic, Petar ^e   Magder, Laurence S ^d   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN C3 HP; APOLIPOPROTEIN C3 R; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LIPOPROTEIN A1; LIPOPROTEIN A2; LIPOPROTEIN B; LIPOPROTEIN C; LIPOPROTEIN D; LIPOPROTEIN E; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADULT; AFRICAN AMERICAN; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; DISEASE ACTIVITY; DOPPLER ECHOGRAPHY; FEMALE; HEART PROTECTION; HUMAN; IMMUNOPRECIPITATION; IMMUNOTURBIDIMETRY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROCEDURES; SLEDAI; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TURBIDIMETRY; ANGIOCARDIOGRAPHY; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; BLOOD; CAROTID ARTERY DISEASES; COMPLICATION; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PREDICTIVE VALUE; RISK FACTOR; VASCULAR CALCIFICATION;

ADULT; APOLIPOPROTEINS; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TOMOGRAPHY, SPIRAL COMPUTED; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR CALCIFICATION;

EID: 84923312195     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22430     Document Type: Article

References (24)

1. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
2. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
3. Alaupovic P, Knight-Gibson C, Wang CS, Downs D, Koren E, Brewer HB Jr, et al. Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res 1991;32:9-19.
4. Nordestgaard BG, Tybaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol 1992;8:92-8.
5. Dahlen EM, Lanne T, Engvall J, Lindstrom T, Grodzinsky E, Nystrom FH, et al. Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with type 2 diabetes. Diabet Med 2009;26:384-90.
6. Kawakami A, Aikawa M, Alcaide P, Luscinskas FE, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006;114:681-7.
7. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-22.
8. Knowlton N, Wages JA, Centola MB, Giles J, Bathon J, Quiroga C, et al. Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:993-1000.
9. Barkia A, Puchois P, Ghalim N, Torpier G, Barbaras R, Ailhaud G, et al. Differential role of apolipoprotein A1-containing particles in cholesterol efflux from adipose cells. Atherosclerosis 1991;87:135-46.
10. Alaupovic P. David Rubenstein Memorial Lecture: the bio-chemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem 1981;59:565-79.
11. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, et al. Apolipoprotein A-1 containing lipoproteins in coronary artery disease. Atherosclerosis 1987;68:35-40.
12. Petri M, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011;70:760-5.
13. Alaupovic P. Use of apolipoprotein parameters and endpoints in drug development and approval processes. Am J Cardiol 1998;81:40-7.
14. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
15. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
16. Budoff MJ, Georgiou D, Brody A, Agatston AS, Kennedy J, Wolfkiel C. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter disease, a multicenter study. Circulation 1996;93:898-904.
17. Smilde TJ, Wollersheim H, Van Langen H. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci (Lond) 1997;93:317-24.
18. Kiani AN, Magder L, Petri M. Coronary calcium in SLE is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008;35:1300-6.
19. Kiani AN, Post W, Magder LS, Petri M. Predictors of progression in subclinical atherosclerosis over two years in systemic lupus erythematosus (SLE). Rheumatology (Oxford) 2011;50:2071-9.
20. Alaupovic P. The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Curr Atheroscler Rep 2003;5:459-67.
21. O'Neill SG, Giles I, Lambrianides A, Manson J, D'Cruz D, Schrieber L, et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:845-54.
22. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy. A review of evidence. J Intern Med 2006;259:493-519.
23. Schmidt C, Wikstrand J. High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year old men: experiences from very long-term follow-up in the AIR study. Atherosclerosis 2009;205:284-9.
24. McMahon M, Grossman J, Skaggs B, FitzGerald J, Sahakian L, Ragavendra N, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009;60:2428-37.